177 related articles for article (PubMed ID: 35612599)
21. A red-light activatable and mitochondrion-targeting Pt
Li Y; Wang Z; Qi Y; Tang Z; Li X; Huang Y
Chem Commun (Camb); 2022 Jul; 58(60):8404-8407. PubMed ID: 35796077
[TBL] [Abstract][Full Text] [Related]
22. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
Chen F; Qin X; Xu G; Gou S; Jin X
Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
[TBL] [Abstract][Full Text] [Related]
23. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
[TBL] [Abstract][Full Text] [Related]
24. Blocking xCT and PI3K/Akt pathway synergized with DNA damage of Riluzole-Pt(IV) prodrugs for cancer treatment.
Li Z; Qiao X; Liu XM; Shi SH; Qiao X; Xu JY
Eur J Med Chem; 2023 Mar; 250():115233. PubMed ID: 36863224
[TBL] [Abstract][Full Text] [Related]
25. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
Wang Z; Xu Z; Zhu G
Angew Chem Int Ed Engl; 2016 Dec; 55(50):15564-15568. PubMed ID: 27736029
[TBL] [Abstract][Full Text] [Related]
26. [Antitumor effects of redox-responsive nanoparticles containing platinum（Ⅳ）in ovarian cancer].
Hou HY; Tang DS; Zhang YN; Wang KY; Ao M; Luo HX; Li B
Zhonghua Zhong Liu Za Zhi; 2024 Jan; 46(1):76-85. PubMed ID: 38246783
[No Abstract] [Full Text] [Related]
27. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
28. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo.
Dhar S; Kolishetti N; Lippard SJ; Farokhzad OC
Proc Natl Acad Sci U S A; 2011 Feb; 108(5):1850-5. PubMed ID: 21233423
[TBL] [Abstract][Full Text] [Related]
29. Targeting SOD1 via RNAi with PEGylated graphene oxide nanoparticles in platinum-resistant ovarian cancer.
Szénási A; Sivasudhan E; Du H; Zhang P; Huang J; Zhang Z; Rocha S; Wang M
Cancer Gene Ther; 2023 Nov; 30(11):1554-1568. PubMed ID: 37582934
[TBL] [Abstract][Full Text] [Related]
30. Fatty acid-like Pt(IV) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36.
Jayawardhana AMDS; Stilgenbauer M; Datta P; Qiu Z; Mckenzie S; Wang H; Bowers D; Kurokawa M; Zheng YR
Chem Commun (Camb); 2020 Sep; 56(73):10706-10709. PubMed ID: 32789350
[TBL] [Abstract][Full Text] [Related]
31. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
Li L; Huang X; Huang R; Gou S; Wang Z; Wang H
Eur J Med Chem; 2018 Aug; 156():666-679. PubMed ID: 30031977
[TBL] [Abstract][Full Text] [Related]
32. Novel monofunctional platinum (II) complex Mono-Pt induces apoptosis-independent autophagic cell death in human ovarian carcinoma cells, distinct from cisplatin.
Guo WJ; Zhang YM; Zhang L; Huang B; Tao FF; Chen W; Guo ZJ; Xu Q; Sun Y
Autophagy; 2013 Jul; 9(7):996-1008. PubMed ID: 23580233
[TBL] [Abstract][Full Text] [Related]
33. Reprogramming axial ligands facilitates the self-assembly of a platinum(iv) prodrug: overcoming drug resistance and safer in vivo delivery of cisplatin.
Fang T; Ye Z; Wu J; Wang H
Chem Commun (Camb); 2018 Aug; 54(66):9167-9170. PubMed ID: 30062328
[TBL] [Abstract][Full Text] [Related]
34. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
[TBL] [Abstract][Full Text] [Related]
35. Cellular and biomolecular responses of human ovarian cancer cells to cytostatic dinuclear platinum(II) complexes.
Lin M; Wang X; Zhu J; Fan D; Zhang Y; Zhang J; Guo Z
Apoptosis; 2011 Mar; 16(3):288-300. PubMed ID: 21107699
[TBL] [Abstract][Full Text] [Related]
36. Design of a novel Pt(II) complex to reverse cisplatin-induced resistance in lung cancer
Jiang M; Yang T; Chu Y; Zhang Z; Sun H; Liang H; Yang F
Dalton Trans; 2022 Mar; 51(13):5257-5270. PubMed ID: 35285843
[TBL] [Abstract][Full Text] [Related]
37. Photoactivatable Prodrug-Backboned Polymeric Nanoparticles for Efficient Light-Controlled Gene Delivery and Synergistic Treatment of Platinum-Resistant Ovarian Cancer.
Zhang Q; Kuang G; He S; Lu H; Cheng Y; Zhou D; Huang Y
Nano Lett; 2020 May; 20(5):3039-3049. PubMed ID: 32250633
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin Prodrug-Loaded Nanoparticles Based on Physalis Mottle Virus for Cancer Therapy.
Hu H; Steinmetz NF
Mol Pharm; 2020 Dec; 17(12):4629-4636. PubMed ID: 33186039
[TBL] [Abstract][Full Text] [Related]
39. Carboplatin prodrug conjugated Fe
Song H; Quan F; Yu Z; Zheng M; Ma Y; Xiao H; Ding F
J Mater Chem B; 2019 Jan; 7(3):433-442. PubMed ID: 32254730
[TBL] [Abstract][Full Text] [Related]
40. Mithplatins: Mithramycin SA-Pt(II) Complex Conjugates for the Treatment of Platinum-Resistant Ovarian Cancers.
Bhosale SS; Mandal A; Hou C; McCorkle JR; Schweer D; Hill KS; Subramanian V; Kolesar JM; Tsodikov OV; Rohr J
ChemMedChem; 2023 Feb; 18(3):e202200368. PubMed ID: 36342449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
